Today: 8 June 2026
Amkor Technology Stock Jumps 6%: Why $1.15 Billion Debt Deal Has AMKR in Focus
9 May 2026
2 mins read

Amkor Technology Stock Jumps 6%: Why $1.15 Billion Debt Deal Has AMKR in Focus

TEMPE, Arizona, May 9, 2026, 11:04 MST

Amkor Technology (AMKR) jumped 6.01% on Friday, ending the session at $76.61. The stock drew renewed attention after a volatile week. Trading volume hit over 5.3 million shares, LSEG data show, as posted on the company’s investor site.

Why does this matter? Amkor has just wrapped up a hefty financing round to fund an advanced packaging capacity push—the technique that brings several chips and memory into closer quarters for faster speeds and lower power use. According to a filing, the company issued $1.15 billion in 0.00% convertible senior notes maturing in 2031, with buyers taking up the full $150 million option.

The notes don’t offer regular interest, and the initial conversion price is set around $106.37 per share—significantly higher than where shares closed on Friday. That structure means Amkor secures funding at a low immediate cash cost, though it does introduce the risk of a conversion overhang down the line if the stock continues to climb.

The timing matters here. Last month, Amkor reported a 27% jump in first-quarter net sales, hitting a new high at $1.685 billion. Net income reached $83 million, or 33 cents per share. CEO Kevin Engel pointed to progress on “key customer programs” in advanced packaging and stronger factory utilization. The company is still aiming for capital spending in 2026 between $2.5 billion and $3.0 billion. Amkor Technology

Amkor’s annual report lays out the case for why the spending numbers matter. The company cites artificial intelligence, high-performance computing, automotive chips, and heterogeneous integration—combining multiple dies in a single package—as the main sources of demand. Its key competitors in packaging and testing are ASE Technology, JCET Group, and Powertech Technology.

The U.S. piece keeps getting bigger. Back in April, Reuters said TSMC wants a chip packaging facility up and running in Arizona by 2029. Amkor, meanwhile, is teaming up with Apple and Nvidia on a separate Arizona packaging site that’s set to launch sooner. Both moves fit into a broader effort to anchor more of the chip supply chain on American soil.

Amkor has moved to curb dilution from its convertible deal by using capped call transactions—these options contracts are designed to partially offset stock issuance or required cash payouts if the notes get converted. The cap is set at $139.50 per share, exactly double the April 30 reference price cited in the offering. Any stock move above that mark isn’t protected by the structure.

Another shot at gauging the company’s outlook comes up soon: Amkor’s 2026 investor day lands in New York on May 21, starting at 9:00 a.m. EDT. Engel, CFO Megan Faust, plus other execs will outline strategy and talk through financial targets.

Director Roger Anthony Carolin was active in the background, according to a Form 4. He exercised options on 20,000 shares at $11.71, then sold the same number of shares on May 5 at a weighted average of $76.24. That leaves Carolin with a direct holding of 94,409 shares.

Still, the expansion isn’t risk-free. On the recent earnings call, Engel flagged delays in customer-supplied materials, describing the impact as “nonlinear loading.” He also pointed to geopolitical tensions in the Middle East applying upward pressure on material costs. So far, Amkor hasn’t experienced supply disruptions tied to those developments. The Motley Fool

Right now, investors see Amkor mainly as a capacity and execution play, not just another company beating earnings. The zero-coupon financing supports that expansion, but the real test is whether advanced-packaging demand ramps up quickly enough to keep margins intact.

Stock Market Today

  • 3 Stocks for Long-Term Hold Despite Market Volatility
    June 8, 2026, 10:08 AM EDT. An investor reveals three stocks they plan to hold for the next 20 years amid potential market corrections and inflation concerns. The picks include Berkshire Hathaway (BRKA, BRKB), known for its diverse holdings and low market sensitivity (beta 0.62), with stable leadership transition following Warren Buffett's 2026 retirement. Intuitive Surgical (ISRG) is highlighted for its dominance in robotic surgical systems, steady recurring revenue from service contracts, and growth through new product approvals. These selections reflect confidence in resilient business models and leadership despite short-term market uncertainty.

Latest articles

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

8 June 2026
Amazon’s new multibillion-dollar supply deal makes Corning a key fiber provider for U.S. data centers, but with shares up 305% in 12 months and investors already pricing in big AI wins, the stock was little changed at $177.58 premarket as risks of factory delays and high expectations loom.
BlackBerry Shares Stall After QNX Push

BlackBerry Stock Moves in Pre-Market Ahead of June Test

8 June 2026
BlackBerry’s U.S. shares rose 2.34% in premarket trading to $9.63 after Friday’s 8.99% drop, but with analyst targets averaging just $4.98, investors are betting on QNX growth and secure-communications wins ahead of June 25 earnings; any disappointment could hit the stock hard.
Micron Technology Stock Surges as AI Memory Shortage Puts MU at Center of Chip Rally

Micron Shares Edge Up in Premarket; Investors Await Next AI Test

8 June 2026
Micron surged 8.2% to $935.07 in Nasdaq premarket after Friday’s $127 billion rout, as investors cheered Nvidia’s confirmation it will keep sourcing high-bandwidth memory from Micron and Samsung, easing fears SK Hynix would become exclusive supplier; Cantor Fitzgerald raised its price target to $1,500, with Micron’s next earnings report due June 24.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
Virgin Galactic Stock Surges 17% Before Earnings: Why SPCE’s Next Test Matters
Previous Story

Virgin Galactic Stock Surges 17% Before Earnings: Why SPCE’s Next Test Matters

eBay Stock Is In Play As GameStop’s Ryan Cohen Digs In On $56 Billion Bid
Next Story

eBay Stock Is In Play As GameStop’s Ryan Cohen Digs In On $56 Billion Bid

Go toTop